In addition to patient tolerability and comfort, keeping a drug at within an optimal therapeutic range in bloodstream helps prevent API waste, thereby reducing treatment costs.
Contact MedinCell to learn of example pain control formulations in which Cmax was substantially reduced, such as Buprenorphine (both 4 day and 1 month durations).
Pain associated with arthritis can be debilitating, and current palliative treatments are not ideal for chronic treatment: viscosupplementation can lead to painful inflammation, opioid-based drugs may induce physical dependency, and NSAIDs can lead to long-term gastrointestinal side effects. Tremendous potential exists for controlled-release osteoarthritis therapies that can be delivered directly to the site of pain or inflammation for improved efficacy and lower systemic toxicity
Contact MedinCell to learn more about our experience with delivering small molecules and antibody APIs via intra-articular injection, as well as recent studies on intra-peritoneal (oncology) and intra-ocular applications of our technology.
MedinCell offers significant advantages for peptide APIs
In addition to our extensive experience with small molecule formulation, MedinCell is dedicated to helping biotech and pharmaceutical companies realize the promise of therapeutic peptides by overcoming half-life and manufacturing challenges. With a single administration, our MedinGel technology can be used to release peptides over days, weeks—even multi-month—therapeutic durations. And, due to the protective nature of the polymer depot, less API is required per day than other delivery methods.
Over 60 peptide APIs have been approved globally, and more than 700 are currently moving through pharmaceutical pipelines. Surpassing the overall pharma growth rate, the peptide market is predicted to reach $15 bilion by 2015.
Peptides demonstrate limited off-target activation of molecular receptors (greater specificity than small molecules). And due to their short half-life, they promise to minimize risks related to toxic accumulation. However, high synthesis costs and frequent injections have limited the widespread acceptance of peptides in drug regimens. Break through the peptide delivery barrier with MedinCell’s novel technology and expand the potential of your peptide products!
Contact MedinCell to explore results for a 1-month antidepressant peptide formulation project, and to hear about our promising experience for protein and antibody delivery.
Adjusting Route of Administration for Patient Preference
Shifting from intramuscular to subcutaneous injections can substantially reduce pain of administration and reduce patient anxiety.
Reducing Societal Burdens
In addition to improving patient lifestyle, a reduced dosing regimen means fewer trips to the clinic and less time off work for patients. In the case of severe illnesses like schizophrenia, nearly 50% non-compliance rate has been reported. For patients that lack the awareness of their condition, non adherence impact is especially clinically disruptive. The total yearly cost of short-term hospital admissions for relapsing schizophrenia patients is over $2 billion in the USA; in fact the WHO ranks schizophrenia as a Top10 cause of years lost because of disability.
MedinCell is actively targeting medical indications that damage global productivity and world economies.
The MedinCell team maintains a global perspective for our business and humanitarian goals. To this end, we endeavor to make products that are as efficacious, convenient, and cost-effective as possible. We share a population-focused view of the world, and strive to develop Best-in-Class treatments for all markets, regardless of local economic conditions.
The MedinGel technology has been refined by years of continuous improvements. Our polymers utilize low-cost components, and avoid scale-up issues common to nano- and microparticles. The platform offers partners a low-risk growth engine to develop novel, competitive therapies. MedinCell’s cGMP partner can produce hundreds of millions of doses per year, and can scale rapidly to meet any market need.
At its core, the MedinGel technology relies on low-cost, safe components. And through its API-sparing nature, the overall treatment costs can be extremely lower. In fact, we are currently developing several products that—fully packaged—will cost less than their generic oral counterparts!
For Enabling humanitarian collaborations (6 and 12 month Ivermectin for River Blindness), and Malaria NCEs